Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,996,818
  • Shares Outstanding, K 42,310
  • Annual Sales, $ 130 K
  • Annual Income, $ -245,870 K
  • 36-Month Beta 1.88
  • Price/Sales 22,537.24
  • Price/Cash Flow 0.00
  • Price/Book 6.05

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.98 +18.09%
on 06/28/17
71.99 -1.61%
on 07/21/17
+5.54 (+8.49%)
since 06/26/17
3-Month
51.67 +37.08%
on 05/31/17
71.99 -1.61%
on 07/21/17
+5.15 (+7.84%)
since 04/26/17
52-Week
51.67 +37.08%
on 05/31/17
91.35 -22.46%
on 03/02/17
+13.64 (+23.85%)
since 07/26/16

Most Recent Stories

More News
Seres Therapeuti is Among the Companies in the Biotechnology Industry with the Best Relative Performance (MCRB, ESPR, PTCT, TGTX, RARE)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ESPR : 49.65 (+1.68%)
PTCT : 20.84 (-1.47%)
TGTX : 11.80 (+3.96%)
MCRB : 14.56 (+3.70%)
RARE : 70.83 (-0.01%)
Watch for Ultragenyx Pharm to Potentially Pullback After Gaining 5.30% Yesterday

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $64.88 to a high of $69.74. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high...

RARE : 70.83 (-0.01%)
Ultragenyx Provides Regulatory Update on Burosumab (KRN23)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has reached agreement with...

RARE : 70.83 (-0.01%)
Ultragenyx to Present at Goldman Sachs 38th Annual Global Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the...

RARE : 70.83 (-0.01%)
Ultragenyx to Present at Jefferies Global Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's...

RARE : 70.83 (-0.01%)
Research Reports Initiation on Biotech Stocks -- Kite Pharma, Arrowhead Pharma, Ultragenyx Pharma, and Jazz Pharma

Focus on Stock-Callers.com this morning is on Kite Pharma Inc. (NASDAQ: KITE), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Jazz Pharmaceuticals PLC...

ARWR : 1.88 (+17.50%)
RARE : 70.83 (-0.01%)
JAZZ : 161.52 (+0.17%)
KITE : 111.24 (+0.65%)
Ultragenyx Receives Priority Review for rhGUS from FDA

The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.

RARE : 70.83 (-0.01%)
VVUS : 1.19 (+0.85%)
BMRN : 89.20 (+0.64%)
SHPG : 169.80 (+2.22%)
Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Biologics License Application...

RARE : 70.83 (-0.01%)
Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE) into...

RARE : 70.83 (-0.01%)
Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate...

RARE : 70.83 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Support & Resistance

2nd Resistance Point 72.12
1st Resistance Point 71.48
Last Price 70.83
1st Support Level 70.10
2nd Support Level 69.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.